<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354640</url>
  </required_header>
  <id_info>
    <org_study_id>J05100, CDR0000485361</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J05100</secondary_id>
    <secondary_id>JHOC-SKCCC-J05100</secondary_id>
    <nct_id>NCT00354640</nct_id>
  </id_info>
  <brief_title>Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer</brief_title>
  <official_title>A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
      or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing,
      or coming back in patients with invasive breast cancer, ductal carcinoma in situ, or a high
      risk of breast cancer.

      PURPOSE: This phase II trial is studying how well giving simvastatin together with
      anastrozole works in treating postmenopausal women with invasive breast cancer, ductal
      carcinoma in situ, or a high risk of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the effects of concurrent anastrozole and simvastatin on anastrozole's
           steady-state concentration in postmenopausal women with history of invasive breast
           cancer or ductal carcinoma in situ or at high risk for developing breast cancer.

      Secondary

        -  Study the effect of concurrent simvastatin and anastrozole on estrogen suppression in
           these patients.

      OUTLINE: This is a pilot study.

      Patients continue to receive oral anastrozole once daily (as prior to study entry). They also
      receive oral simvastatin once daily for 14-18 days in the absence of unacceptable toxicity or
      diagnosis of new or recurrent breast cancer.

      Patients undergo blood sample collection at baseline and after study therapy for analysis of
      anastrozole and hormone (estradiol and estrogen) concentrations.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Concentrations</measure>
    <time_frame>Baseline and 14 days</time_frame>
    <description>The change in blood concentrations of anastrozole at baseline and 14 days was measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Estradiol Levels</measure>
    <time_frame>Baseline and 14 days</time_frame>
    <description>The change in serum concentrations of estradiol at baseline and 14 days was measured.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Anastrozole and Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>1 milligram tablet PO QD for 14 days</description>
    <arm_group_label>Anastrozole and Simvastatin</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>40 milligram tablet PO QD for 14 days</description>
    <arm_group_label>Anastrozole and Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>laboratory analysis</description>
    <arm_group_label>Anastrozole and Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>laboratory analysis</description>
    <arm_group_label>Anastrozole and Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets any of the following criteria:

               -  History of invasive breast cancer

               -  History of ductal carcinoma in situ

               -  At high risk for breast cancer, defined as being on anastrozole for
                  chemoprevention of breast cancer

          -  Receiving anastrozole for ≥ 30 days as adjuvant breast cancer treatment or for
             prevention of breast cancer

          -  No active breast cancer with known metastatic involvement

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal

          -  ECOG performance status 0-2

          -  AST and ALT ≤ 3 times upper limit of normal

          -  Creatinine clearance ≥ 30 mL/min

          -  No active liver disease

          -  No prior hypersensitivity to any HMG-CoA reductase inhibitor or any of its components

          -  No daily alcohol use of &gt; 3 standard drinks/day

               -  A standard drink is defined as 10 g of alcohol, which is equivalent to 285 mL of
                  beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No cholesterol-lowering drug, including a statin, within the past 3 months

          -  No selective estrogen receptor modulator (SERM) within the past 3 months

          -  No other hormone therapy within the past 3 months

          -  No prior estrogen and/or progesterone hormone replacement therapy that lasted for ≥ 5
             years

               -  Vaginal estrogen preparations allowed

          -  No other concurrent statin or cholesterol-lowering drug

          -  No other concurrent SERM

          -  No other concurrent hormone therapy

          -  No other concurrent investigational drugs

          -  No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, erythromycin,
             clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or cyclosporine

          -  No concurrent chemotherapy or biological agents

          -  No concurrent daily grapefruit juice &gt; 8 oz/day

          -  No other concurrent anticancer agents or therapies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2013</results_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eleven women were enrolled from December 2006 to September 2008.</recruitment_details>
      <pre_assignment_details>Women were required to be taking anastrozole as adjuvant treatment for breast cancer.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Anastrozole and Simvastatin</title>
          <description>adjuvant therapy : laboratory analysis
pharmacological study : laboratory analysis
simvastatin : 40 milligram tablet PO QD for 14 days
anastrozole : 1 milligram tablet PO QD for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anastrozole and Simvastatin</title>
          <description>adjuvant therapy : laboratory analysis
pharmacological study : laboratory analysis
simvastatin : 40 milligram tablet PO QD for 14 days
anastrozole : 1 milligram tablet PO QD for 14 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Blood Concentrations</title>
        <description>The change in blood concentrations of anastrozole at baseline and 14 days was measured.</description>
        <time_frame>Baseline and 14 days</time_frame>
        <population>Participants with blood samples for trough concentrations were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole and Simvastatin</title>
            <description>adjuvant therapy : laboratory analysis
pharmacological study : laboratory analysis
simvastatin : 40 milligram tablet PO QD for 14 days
anastrozole : 1 milligram tablet PO QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Concentrations</title>
          <description>The change in blood concentrations of anastrozole at baseline and 14 days was measured.</description>
          <population>Participants with blood samples for trough concentrations were included.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anastrozole concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="-6.2" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydroxyanastrozole concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.14" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Estradiol Levels</title>
        <description>The change in serum concentrations of estradiol at baseline and 14 days was measured.</description>
        <time_frame>Baseline and 14 days</time_frame>
        <population>Participants with blood samples for trough concentrations were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole and Simvastatin</title>
            <description>adjuvant therapy : laboratory analysis
pharmacological study : laboratory analysis
simvastatin : 40 milligram tablet PO QD for 14 days
anastrozole : 1 milligram tablet PO QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Estradiol Levels</title>
          <description>The change in serum concentrations of estradiol at baseline and 14 days was measured.</description>
          <population>Participants with blood samples for trough concentrations were included.</population>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-19.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <desc>Participants were assessed by a member of the study team at the end of simvastatin dosing.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anastrozole and Simvastatin</title>
          <description>adjuvant therapy : laboratory analysis
pharmacological study : laboratory analysis
simvastatin : 40 milligram tablet PO QD for 14 days
anastrozole : 1 milligram tablet PO QD for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, difficulty in recruiting due to women either already taking a statin or on a different aromatase inhibitor.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Vered Stearns</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>4432876489</phone>
      <email>vstearn1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

